Real-world hospital treatment patterns in Belgium in early lung cancer between 2018 and 2023: a secondary data analysis [BE-LUNG]

Study identification

• EU PAS number:
  EUPAS1000000397
• Study ID:
  1000000397
• Official title and acronym:
  Real-world hospital treatment patterns in Belgium in early lung cancer between 2018 and 2023: a secondary data analysis [BE-LUNG]
• DARWIN EU® study:
  No
• Study countries:
  Belgium
• Study description:
  This multicenter study describes treatment patterns in Belgian patients with stage I-III lung cancer in the period 2018-2023 by leveraging natural language processing and the OMOP common data model.
• Study status:
  Finalised

Research institutions and networks

Institutions

AZ Maria Middelares General Hospital

Belgium

AstraZeneca

Universitair Ziekenhuis Antwerpen (UZA)

Belgium

LynxCare Clinical Informartics

Belgium

Algemeen Ziekenhuis Groeninge; Universitair Ziekenhuis Brussel

Study timelines

Date when funding contract was signed

Actual:15/05/2024

Study start date

Actual:06/12/2024

Date of final study report

Planned:28/02/2025

Actual:30/04/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca BeLux

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable